80wk Uptrend — rising+above (sma 24.24 vs px 40.50)
200wk Uptrend — rising+above (sma 20.18 vs px 40.50)
Funds Accumulating — momZ +5.33 · 2.45→2.77
Seasonal Tailwind — july med 10% (mag 2/3) · posClose 72.73% (rel 2/3) · n11 ×1 = 8
Hidden Gem — stWatch 254
About Indivior PLC Ordinary Shares
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; a… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Exchange: NASDAQ
IPO Date: December 29, 2014
Headquarters: 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235
Hidden Gem: Yes — undiscovered relative to its market cap tier
Founder-Led: No
Key Metrics
Current Price
$40.50
Market Cap
$4.88B
Float
112.9M
Shares Outstanding
118.2M
P/E (Forward)
13.39
P/E (TTM)
20.96
Price/Sales (TTM)
3.78
vs. Analyst Target
+25.5% to analyst PT
Profit Margin
19.53%
Operating Margin (TTM)
46.06%
Revenue (TTM)
$1.29B
Earnings Growth (YoY)
82.00%
Dividend Rate
None
Analyst Target Price
$50.83 (7 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$647M
-$148M
$550M
-$123M
2021
$791M
$205M
$664M
$238M
2022
$901M
-$44.0M
$750M
-$46.0M
2023
$1.09B
-$129M
$919M
-$99.0M
2024
$1.19B
$2.0M
$957M
$84.0M
2025
$1.24B
$210M
$993M
$304M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$302M
$18.0M
Sep 2025
$314M
$42.0M
Dec 2025
$358M
$102M
Mar 2026
$317M
$89.0M
Ownership & Float
Insider Ownership
2.0%
Institutional Ownership
108.9%
Short Float
10.5%
% of All Funds Holding
2.77%
Number of Funds Holding
214
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$38.63
Near-term / short-term trend
Weekly
40-Week SMA
$33.83
Medium-term trend
Weekly
80-Week SMA
$24.24
Cyclical trend (business cycle)
Weekly
200-Week SMA
$20.18
Secular trend (multi-year)
Monthly
10-Month SMA
$35.18
Near-term monthly trend
Monthly
20-Month SMA
$25.13
Medium-term monthly trend
Monthly
40-Month SMA
$21.25
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Indivior PLC Ordinary Shares
(INDV) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.